Eric P. Winer
Impact in
- Cancer Research top 0.01%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
- Oncology 419
- Cancer Treatment and Pharmacology 166
- HER2/EGFR in Cancer Research 140
- Cancer Immunotherapy and Biomarkers 47
- Cancer Research 247
- Breast Cancer Treatment Studies 196
- Cancer Genomics and Diagnostics 57
- Co-authors
- Adrienne G. Waks (25 shared papers)Harold J. Burstein (96 shared papers)Nancy U. Lin (154 shared papers)Ann H. Partridge (116 shared papers)Clifford A. Hudis (107 shared papers)Hope S. Rugo (51 shared papers)Donald A. Berry (46 shared papers)Lisa A. Carey (72 shared papers)
- Journals
- Journal of Clinical Oncology (273 papers)Cancer Research (68 papers)Breast Cancer Research and Treatment (55 papers)Annals of Oncology (36 papers)Clinical Cancer Research (29 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Eric P. Winer
727 papers receiving 56.5k citations
Eric P. Winer's Hit Papers
Peers
Comparison fields: 5 of 182
- Cancer Research 15.9k
- Oncology 28.0k
- Family Practice 713
- Pulmonary and Respiratory Medicine 11.0k
- Pathology and Forensic Medicine 3.1k
Countries citing papers authored by Eric P. Winer
This map shows the geographic impact of Eric P. Winer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric P. Winer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric P. Winer more than expected).
Fields of papers citing papers by Eric P. Winer
This network shows the impact of papers produced by Eric P. Winer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric P. Winer. The network helps show where Eric P. Winer may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric P. Winer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 743 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Breast Cancer Treatment Hit paper breakdown → | 2019 | 3356 |
| 2 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3084 |
| 3 | American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer Hit paper breakdown → | 2005 | 1373 |
| 4 | CDK4/6 inhibition triggers anti-tumour immunity Hit paper breakdown → | 2017 | 1033 |
| 5 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 877 |
| 6 | Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343 Hit paper breakdown → | 2013 | 837 |
| 7 | Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer Hit paper breakdown → | 2004 | 736 |
| 8 | Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Hit paper breakdown → | 1999 | 694 |
| 9 | Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 Hit paper breakdown → | 2014 | 688 |
| 10 | Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance) Hit paper breakdown → | 2014 | 658 |
| 11 | Triple-negative breast cancer: disease entity or title of convenience? Hit paper breakdown → | 2010 | 657 |
| 12 | American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer Hit paper breakdown → | 2010 | 613 |
| 13 | Web-Based Survey of Fertility Issues in Young Women With Breast Cancer Hit paper breakdown → | 2004 | 588 |
| 14 | Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update Hit paper breakdown → | 2014 | 565 |
| 15 | Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma Hit paper breakdown → | 2003 | 557 |
| 16 | Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer Hit paper breakdown → | 2008 | 557 |
| 17 | Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer Hit paper breakdown → | 2003 | 555 |
| 18 | CNS Metastases in Breast Cancer Hit paper breakdown → | 2004 | 548 |
| 19 | Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer Hit paper breakdown → | 2006 | 518 |
| 20 | Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500 Hit paper breakdown → | 2014 | 488 |
About Eric P. Winer
Eric P. Winer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Molecular Biology, having authored 743 papers that have together received 57.6k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (196 papers), Cancer Treatment and Pharmacology (166 papers), Advanced Breast Cancer Therapies (156 papers), HER2/EGFR in Cancer Research (140 papers), Cancer Genomics and Diagnostics (57 papers), Cancer Immunotherapy and Biomarkers (47 papers), BRCA gene mutations in cancer (41 papers) and Brain Metastases and Treatment (41 papers). The work is most often cited by research in Cancer Research (15.9k citations), Oncology (28.0k citations), Family Practice (713 citations), Pulmonary and Respiratory Medicine (11.0k citations) and Pathology and Forensic Medicine (3.1k citations). Eric P. Winer has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Adrienne G. Waks, Harold J. Burstein, Nancy U. Lin, Ann H. Partridge, Clifford A. Hudis, Hope S. Rugo, Donald A. Berry, Lisa A. Carey, Ian E. Krop and Constance Cirrincione. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Annals of Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.